 |
|
|
|
 |
A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adults with Hematological Cancers
[Protocol 07-072]
- Full Title :
- A PHASE II MULTICENTER TRIAL OF MYELOABLATIVE DOUBLE UNIT UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) IN ADULTS WITH HEMATOLOGIC MALIGNANCY (CIBMTR #05-DCB)
- Purpose :
The purpose of this study is to evaluate the effectiveness of giving stem cells from the umbilical cord blood of two newborn infants to patients with hematological cancers that are advanced or at high risk of relapse. Patients will first receive a combination of chemotherapy drugs (cyclophosphamide and fludarabine) and whole-body irradiation to further treat their cancer. The goal of the transplanted stem cells is to repopulate the patient's bone marrow with healthy cells, and create a new donor immune system to protect against relapse.
However, a single donor cord blood transplant may not contain enough cells to ensure recovery of the patient's bone marrow after chemotherapy. Therefore, in this study two cord blood collections will be used to increase the number of cord blood cells patients receive. This approach is called a "double unit" cord blood transplant. A previous study suggests double unit cord blood transplantation may be more effective than a single-cord transplant.
The main purpose of this research is to determine the effectiveness of a double unit cord blood transplant for treating hematological cancers, and to see if this treatment influences a patient's survival after the transplant. Cord blood is infused into the recipient's blood stream through a catheter (just like a blood transfusion).
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of acute myelogenous leukemia, acute lymphoblastic leukemia, acute undifferentiated leukemia, or myelodysplastic syndrome that is advanced, relapsed, or in first or second remission and at high risk of relapse. (These criteria will differ according to which type of hematological cancer the patient has.)
- Patients may not have had a prior stem cell transplant.
- Patients must be ages 22 to 50.
For more information and to see if you are eligible for this study, please contact Dr. Juliet Barker at 212-639-3468.
|
|
|
|
|
